91 Sustained Therapeutic Benefit of Vedolizumab Throughout 1 Year in Crohn's Disease in Gemini II, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Study

Poster presentations (29.5%) needed dose escalation of ADA which was successful in re-inducing remission in 6 patients and two of these 6 patients were able to de-escalate treatment.Only 14 (20.5%) of the patients stopped ADA.

Vedolizumab

10.1016/s1873-9946(14)60608-5

Cite

Citations (2)

Faculty Opinions recommendation of Vedolizumab as induction and maintenance therapy for Crohn's disease.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature (2013)

Guy A. Zimmerman

Vedolizumab

Maintenance therapy

10.3410/f.718083272.793482882

Cite

Citations (0)

Vedolizumab for induction and maintenance of remission in Crohn’s disease

Cochrane library (2020)

Samuel Hui Anuj Krishna Nik S. Ding Ray Boyapati

Vedolizumab

Maintenance therapy

10.1002/14651858.cd013611

Cite

Citations (1)

Tu1268 Effect of Vedolizumab on Health-Related Quality of Life in Patients With Crohn's Disease

Gastroenterology (2015)

William J. Sandborn Walter Reinisch Edward V. Loftus Remo Panaccione Helen Doll

Vedolizumab

10.1016/s0016-5085(15)32856-0

Cite

Citations (0)

Vedolizumab for the treatment of ulcerative colitis

Expert Opinion on Biological Therapy (2015)

Neal Shahidi Brian Bressler Remo Panaccione

With a need for a larger armamentarium of therapeutic options for those suffering from moderate-to-severe ulcerative colitis, vedolizumab, an α4β7-integrin biologic therapy, has recently received approval in the United States, Canada and Europe. However, it is unclear where it should be positioned in relation to current therapies for moderate-to-severe ulcerative colitis.We systematically reviewed the literature for phase 1, phase 2 and phase 3 randomized controlled trials assessing the role of vedolizumab in ulcerative colitis.Trials assessing vedolizumab highlight its arrival as an effective and safe therapy for patients suffering from ulcerative colitis.

Vedolizumab

10.1517/14712598.2016.1121231

Cite

Citations (2)

Mo1845 - Higher Serum Concentrations of Vedolizumab are Associated with Superior Endoscopic Outcomes in Crohn's Disease: Data from the Love-CD Trial

Gastroenterology (2018)

Sophie E. Berends Mark Löwenberg Filip J. Baert Ron A. A. Mathôt E Clasquin

Vedolizumab

10.1016/s0016-5085(18)32809-9

Cite

Citations (1)

Sa1256 Vedolizumab for Induction of Remission in Crohn's Disease in Adults, a Systematic Review and Meta-Analysis